Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test
Takanori Teshima(Hokkaido University Hospital), Yasutaka Kakinoki(Asahikawa City Hospital), Hiroshi Iwasaki(Wakayama Medical University), Seisho Ando(Asahikawa Medical University), Masumi Tsuda(Hokkaido University), Mitsutoshi Kurosawa(Hokkaido University), Shuichi Ota(National Hospital Organization Hokkaido Medical Center), Motohiro Shindo(Asahikawa Medical University), Akio Mori(Juntendo University), Yusuke Ohba(University of Tsukuba), Takeshi Kondo(Shinko Hospital), Shinichi Fujisawa(Hokkaido University Hospital), Satoshi Yamamoto(Tonan Hospital), Kaori Sato(Hokkaido University), Yoshihito Haseyama(Tonan Hospital), Yoichiro Fujioka(Hokkaido University of Science), Takuto Miyagishima(Kushiro Rosai Hospital)
Cited by 5
Related Papers
Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
|Nature Immunology|2012|832
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2020|739
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523